What's breaking now, across thousands of outlets.
Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.
We haven't written up this one. MarketWatch has the full story — the link below goes straight to it.
Type 1 diabetes isn't an overnight attack against the body's ability to make insulin. It can be a sustained campaign over years that relentlessly targets insulin-producing cells in the pancreas.
Long-term research finds most children recovered from the effects of the pandemic.
(MedPage Today) -- Cardiologists Ronald Karlsberg, MD, and Venkatesh Murthy, MD, PhD, are among the new appointees to the U.S. Preventive Services Task Force (USPSTF).
"We were able to show that the loss of the Y chromosome is found in normal appearing tissues adjacent to a tumor."
Brittany Romano says Patrick Clancy's "60 Minutes" interview missed key questions and overlooked postpartum psychosis.
"Feeding and observing birds is a really meaningful way for people to connect with nature, and people feel that it has positive impacts on their well-being."
